Research in Context is a structured summary that editors at The Lancet’s journals ask all authors to provide when submitting an original research article. Read more
Stay at the forefront of non-small cell lung cancer care with insights from the Lancet family of journals, featuring groundbreaking research and authoritative reviews that inform the latest advances in diagnosis, treatment, and patient care.
Investigators reported significantly improved progression-free survival versus aumolertinib monotherapy, with no new safety signals; the authors describe the combination as a potential first-line alternative, not an established standard.
The Lancet Group reaches millions of clinicians and researchers worldwide.
In this study, generalisability not yet established, with a global phase 3 underway to assess it, the authors reported that first-line ivonescimab plus chemotherapy significantly improved overall survival versus tislelizumab plus chemotherapy, with a manageable safety profile.
In OptiTROP-Lung05, investigators reported that this combination significantly prolonged progression-free survival versus pembrolizumab alone; the authors describe the results as a foundation for further defining ADC–immunotherapy strategies.
KROCUS trial authors caution that randomised validation is still needed, while reporting encouraging anti-tumour activity for this investigational combination, which they describe as holding potential as a chemotherapy-free, immunotherapy-free option.
A Lancet Regional Health – Western Pacific Research in Context piece reports durable responses and median overall survival outcomes with savolitinib in previously treated and treatment-naïve patients with MET exon 14-mutated NSCLC.
In this interim analysis, in Chinese patients with EGFR mutation-positive NSCLC and MET amplification after first-line EGFR TKI failure, investigators reported prolonged investigator-assessed PFS with the combination versus chemotherapy.
In Chinese patients with completely resected stage II–IIIA disease, investigators reported improved disease-free survival with adjuvant aumolertinib versus placebo; overall survival was not reported.
In patients ineligible for, unsuccessfully treated with, or refusing standard chemotherapy, researchers reported antitumour activity with the investigational agent vebreltinib; a phase 3 comparison with standard treatment is being initiated.
A prospective study reports feasibility of pembrolizumab plus chemotherapy without radiotherapy; the authors say a randomised trial is required before comparison with standard chemoradiotherapy–durvalumab care.
A reconstructed individual patient data meta-analysis of randomised phase 3 trials reported similar overall survival overall, with a subgroup benefit for dual blockade reported in PD-L1 TPS less than 1% and STK11-mutated tumours.